Voices
Herbert Loong: EGFR-Mutant NSCLC Management in the Era of FLAURA2 and MARIPOSA
Herbert Loong/X

Herbert Loong: EGFR-Mutant NSCLC Management in the Era of FLAURA2 and MARIPOSA

Herbert Loong, Advisor at Greater Bay Area International Clinical Trial Institute, shared on LinkedIn:

“Had opportunity to discuss updates in EGFR, NSCLC management w/ colleagues in Vietnam earlier this week. Now that we have FLAURA2 and MARIPOSA, how should we choose?

Lots of very interesting and challenges cases being presented! Thanks for your sharing!”

You might be interested in:

MARIPOSA: Amivantamab Plus Lazertinib Reduces EGFR/MET Resistance and Extends Second-Line Disease Control in EGFR-Mutated NSCLC

Herbert Loong: EGFR-Mutant NSCLC Management in the Era of FLAURA2 and MARIPOSA

 

 

cancer EGFR FLAURA2 Herbert Loong MARIPOSA NSCLC OncoDaily Oncology Vietnam